Q1 EPS Forecast for Amylyx Pharmaceuticals Lifted by Analyst

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) – Research analysts at HC Wainwright upped their Q1 2026 earnings per share (EPS) estimates for shares of Amylyx Pharmaceuticals in a note issued to investors on Wednesday, March 4th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of ($0.34) for the quarter, up from their prior forecast of ($0.40). HC Wainwright has a “Buy” rating and a $34.00 price objective on the stock. The consensus estimate for Amylyx Pharmaceuticals’ current full-year earnings is ($2.20) per share. HC Wainwright also issued estimates for Amylyx Pharmaceuticals’ Q2 2026 earnings at ($0.34) EPS, Q3 2026 earnings at ($0.34) EPS, Q4 2026 earnings at ($0.34) EPS, FY2026 earnings at ($1.34) EPS, FY2027 earnings at ($1.25) EPS, FY2028 earnings at ($0.93) EPS, FY2029 earnings at $1.83 EPS and FY2030 earnings at $3.93 EPS.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.01.

Several other equities analysts have also recently commented on the stock. Wall Street Zen cut shares of Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, December 20th. Stifel Nicolaus assumed coverage on Amylyx Pharmaceuticals in a research note on Tuesday. They set a “buy” rating and a $21.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research report on Monday, December 29th. Finally, Bank of America boosted their price target on Amylyx Pharmaceuticals from $15.00 to $19.00 and gave the company a “buy” rating in a report on Friday, February 20th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Amylyx Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.56.

Amylyx Pharmaceuticals Price Performance

NASDAQ AMLX opened at $14.10 on Friday. The company has a market capitalization of $1.56 billion, a price-to-earnings ratio of -9.10 and a beta of -0.31. Amylyx Pharmaceuticals has a 12 month low of $3.11 and a 12 month high of $17.49. The company’s fifty day moving average price is $13.91 and its two-hundred day moving average price is $13.17.

Insider Buying and Selling

In other Amylyx Pharmaceuticals news, CFO James M. Frates sold 3,326 shares of the stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $11.11, for a total value of $36,951.86. Following the sale, the chief financial officer directly owned 177,104 shares of the company’s stock, valued at $1,967,625.44. This trade represents a 1.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Justin B. Klee sold 1,995 shares of the business’s stock in a transaction on Friday, January 16th. The shares were sold at an average price of $13.89, for a total transaction of $27,710.55. Following the transaction, the chief executive officer directly owned 3,379,398 shares of the company’s stock, valued at approximately $46,939,838.22. This trade represents a 0.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 151,203 shares of company stock valued at $2,028,385 over the last quarter. Company insiders own 12.30% of the company’s stock.

Institutional Trading of Amylyx Pharmaceuticals

Several hedge funds have recently bought and sold shares of AMLX. Adage Capital Partners GP L.L.C. boosted its stake in Amylyx Pharmaceuticals by 54.5% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 8,800,000 shares of the company’s stock valued at $56,408,000 after purchasing an additional 3,102,395 shares during the period. Perceptive Advisors LLC raised its holdings in shares of Amylyx Pharmaceuticals by 0.4% during the second quarter. Perceptive Advisors LLC now owns 7,902,365 shares of the company’s stock valued at $50,654,000 after buying an additional 28,017 shares during the last quarter. TCG Crossover Management LLC boosted its position in shares of Amylyx Pharmaceuticals by 5.0% during the third quarter. TCG Crossover Management LLC now owns 6,243,812 shares of the company’s stock worth $84,853,000 after buying an additional 300,000 shares during the period. Vanguard Group Inc. boosted its position in shares of Amylyx Pharmaceuticals by 10.1% during the fourth quarter. Vanguard Group Inc. now owns 5,804,912 shares of the company’s stock worth $70,123,000 after buying an additional 531,162 shares during the period. Finally, Commodore Capital LP grew its holdings in Amylyx Pharmaceuticals by 38.6% in the 4th quarter. Commodore Capital LP now owns 5,650,000 shares of the company’s stock worth $68,252,000 after buying an additional 1,574,522 shares in the last quarter. 95.84% of the stock is currently owned by institutional investors.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.